2. Academic Validation
  3. Diagnosis and management of type I and type V hyperlipoproteinemia

Diagnosis and management of type I and type V hyperlipoproteinemia

  • J Atheroscler Thromb. 2012;19(1):1-12. doi: 10.5551/jat.10702.
Takanari Gotoda 1,  Koji Shirai,  Takao Ohta,  Junji Kobayashi,  Shinji Yokoyama,  Shinichi Oikawa,  Hideaki Bujo,  Shun Ishibashi,  Hidenori Arai,  Shizuya Yamashita,  Mariko Harada-Shiba,  Masaaki Eto,  Toshio Hayashi,  Hirohito Sone,  Hiroaki Suzuki,  Nobuhiro Yamada,  Research Committee for Primary Hyperlipidemia, Research on Measures against Intractable Diseases by the Ministry of Health, Labour and Welfare in Japan
Affiliations

Affiliation

  • 1 Department of Clinical and Molecular Epidemiology, 22nd Century Medical and Research Center, University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan. gotoda-tky@umin.ac.jp
PMID: 22129523 DOI: 10.5551/jat.10702
Abstract

Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein Lipase (LPL)- Apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.

Figures